(total of 8.B 1 + 8.B 2) Total of both in % (8.A + 8.B) Total number of voting rights of issuervii Resulting situation on the date on which threshold was crossed or reached 2.95 % 2.14 % 5.09 % 81,901,173 Position of previous notification (if
applicable)
shares
ISIN code (if possible) Number of voting rightsix % of voting rights Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1) Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1) Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1) Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1) GB00BN40HZ01 2,418,076 2.95 % SUBTOTAL 8. A 2,418,076 2.95 %
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) Type of financial instrument Expiration
datex Exercise/
Conversion Periodxi Number of voting rights that may be acquired if the instrument is
exercised/converted. % of voting rights American Depositary Shares (ADS) N/A N/A 1,750,000 2.14 % SUBTOTAL 8. B 1 1,750,000 2.14 %
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) Type of financial instrument Expiration
datex Exercise/
Conversion Period xi Physical or cash
settlementxii Number of voting rights % of voting rights SUBTOTAL 8.B.2
applicable box with an “X”) Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary) Namexv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold 10. In case of proxy voting, please identify: Name of the proxy holder The number and % of voting rights held The date until which the voting rights will be held 11. Additional informationxvi Summit Therapeutics PLC (“SUMM”) is dual listed. We hold SUMM on the London line and in the US with ADRs. Our US and UK holdings are each both below the threshold reporting and therefore were not disclosed. However, it has come to our attention that the respective holdings should be aggregated. On an aggregated basis, we can confirm we crossed the reporting threshold on March 27th 2018.
Please accept our disclosure of today’s date (30th November 2018) as a retrospective notification for the threshold crossing on 27th March 2018.